![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 7, 4951-4958, February 15, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Radiation Oncology and the Winship Cancer
Institute, Emory University School of Medicine,
Atlanta, Georgia 30322
Aberrant methylation of CpG-dense
islands in the promoter regions of genes is an acquired epigenetic
alteration associated with the silencing of tumor suppressor genes in
human cancers. In a screen for endogenous targets of
methylation-mediated gene silencing, we identified a novel CpG
island-associated gene, TMS1, which is aberrantly
methylated and silenced in response to the ectopic expression of DNA
methyltransferase-1. TMS1 functions in the regulation of apoptosis and
is frequently methylated and silenced in human breast cancers. In this
study, we characterized the methylation pattern and chromatin
architecture of the TMS1 locus in normal fibroblasts and
determined the changes associated with its progressive methylation. In
normal fibroblasts expressing TMS1, the CpG island is
defined by an unmethylated domain that is separated from densely
methylated flanking DNA by distinct 5' and 3' boundaries. Analysis of
the nucleoprotein architecture of the locus in intact nuclei revealed
three DNase I-hypersensitive sites that map within the CpG
island. Strikingly, two of these sites coincided with the 5'-
and 3'-methylation boundaries. Methylation of the TMS1 CpG
island was accompanied by loss of hypersensitive site formation,
hypoacetylation of histones H3 and H4, and gene silencing. This altered
chromatin structure was confined to the CpG island and occurred without
significant changes in methylation, histone acetylation, or
hypersensitive site formation at a fourth DNase I-hypersensitive site 2 kb downstream of the TMS1 CpG island. The data indicate
that there are sites of protein binding and/or structural transitions
that define the boundaries of the unmethylated CpG island in normal
cells and that aberrant methylation overcomes these boundaries to
direct a local change in chromatin structure, resulting in gene silencing.
To whom correspondence should be addressed: Winship Cancer
Institute, Emory University School of Medicine, 1365-B Clifton Rd., NE,
Rm. B5119, Atlanta, GA 30322. Tel.: 404-778-3119; Fax: 404-778-3965;
E-mail: pvertin@emory.edu.
This article has been cited by other articles:
![]() |
M. Esteller Epigenetic gene silencing in cancer: the DNA hypermethylome Hum. Mol. Genet., April 15, 2007; 16(R1): R50 - R59. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Fish, C. C. Matouk, A. Rachlis, S. Lin, S. C. Tai, C. D'Abreo, and P. A. Marsden The Expression of Endothelial Nitric-oxide Synthase Is Controlled by a Cell-specific Histone Code J. Biol. Chem., July 1, 2005; 280(26): 24824 - 24838. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Stone, W. Bobo, D. J. Brat, N. S. Devi, E. G. Van Meir, and P. M. Vertino Aberrant Methylation and Down-Regulation of TMS1/ASC in Human Glioblastoma Am. J. Pathol., October 1, 2004; 165(4): 1151 - 1161. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Terasawa, S. Sagae, M. Toyota, K. Tsukada, K. Ogi, A. Satoh, H. Mita, K. Imai, T. Tokino, and R. Kudo Epigenetic Inactivation of TMS1/ASC in Ovarian Cancer Clin. Cancer Res., March 15, 2004; 10(6): 2000 - 2006. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Yates, R. Burman, J. Simpson, O. N. Ponomoreva, M. J. Thayer, and M. S. Turker Silencing of Mouse Aprt Is a Gradual Process in Differentiated Cells Mol. Cell. Biol., July 1, 2003; 23(13): 4461 - 4470. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Chen, S. Toyooka, A. F. Gazdar, and J.-T. Hsieh Epigenetic Regulation of a Novel Tumor Suppressor Gene (hDAB2IP) in Prostate Cancer Cell Lines J. Biol. Chem., January 24, 2003; 278(5): 3121 - 3130. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |